Autolus Therapeutics plc (AUTL)

USD 2.29

(-8.03%)

Market Cap (In USD)

609.41 Million

Revenue (In USD)

1.69 Million

Net Income (In USD)

-208.38 Million

Avg. Volume

966.47 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.29-7.45
PE
-
EPS
-
Beta Value
2.039
ISIN
US05280R1005
CUSIP
05280R100
CIK
1730463
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Christian Martin Itin Ph.D.
Employee Count
-
Website
https://www.autolus.com
Ipo Date
2018-06-22
Details
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.